Anti‐secretory effects and pharmacokinetics of low dose ranitidine
- 1 August 1993
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 7 (4) , 417-422
- https://doi.org/10.1111/j.1365-2036.1993.tb00115.x
Abstract
SUMMARY: The purpose of this study was to examine the anti‐secretory effect of low doses of orally administered ranitidine on meal‐stimulated gastric acid secretion and assess its pharmacokinetics. The effect of 20, 40, 60 and 80 mg of ranitidine p.o. and placebo were tested on 5 separate days (Latin square, double‐blind) in 15 healthy males (mean age 35 years). Gastric acid secretion was measured prior to and for 8 h following two sequential mixed liquid meals administered at 4‐h intervals. Venous blood samples were obtained at frequent intervals before and following each dose for determination of plasma ranitidine concentration by high pressure liquid chromatography. Each dose of ranitidine significantly (P < 0.01) decreased the peak and cumulative 4‐h acid secretory responses to the first meal (range 58–93 %), and the 60 and 80 mg doses significantly inhibited the response to the second meal by 31 and 43%, respectively. Total 8‐h meal‐stimulated acid outputs were decreased significantly in a dose‐related manner (range 38–73%). Peak plasma ranitidine occurred approximately 1 h after dosing. Ranitidine tmax, t½ and clearances were independent of dose; however, AUC and C. were dose‐related. Inhibition of acid secretion was related to plasma ranitidine concentration; the mean IC50 was 27 (± 6.4) ng/ml. We conclude that modest doses (equivalent to 7–27% of the daily therapeutic dose) of ranitidine effectively suppress meal‐stimulated gastric acid secretion in a dose‐related manner. If these doses are of clinical efficacy, it may be possible for substantial cost savings to occur.Keywords
This publication has 12 references indexed in Scilit:
- An academic medical centerʼs experience with mandatory managed care for Medicaid recipientsAcademic Medicine, 1991
- Effect of Basal Gastric Acid Secretion on the Pharmacodynamics of RanitidineChronobiology International, 1991
- NSAID-Induced Gastrointestinal DamageJournal of Clinical Gastroenterology, 1990
- Twenty‐four‐hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times dailyAlimentary Pharmacology & Therapeutics, 1989
- Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcerThe American Journal of Medicine, 1986
- Comparison of the serial dilution indicator and intragastric titration methods for measurement of meal-stimulated gostric acid secretion in manDigestive Diseases and Sciences, 1983
- Clinical comparison of cimetidine and ranitidineClinical Pharmacology & Therapeutics, 1982
- Analysis of Ranitidine in Serum by High Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1980
- INHIBITION OF PENTAGASTRIN-STIMULATED AND NOCTURNAL GASTRIC SECRETION BY RANITIDINEThe Lancet, 1979
- Effect of fat on meal-stimulated duodenal acid load, duodenal pepsin load, and serum gastrin in duodenal ulcer and normal subjectsGastroenterology, 1978